Pharmacogenetic Testing

Abstract

BACKGROUND: Despite extensive scholastic and professional training, medication management in psychiatry is often relegated to trial-and-error prescribing. Pharmacogenetic testing (PGT) may expedite identification of medications with maximal efficacy and minimal side effects by recognizing individual genetic variability in drug response. OBJECTIVES: This article outlines the background of PGT, explains drug metabolism, and evaluates the impact of PGT. DESIGN: A review of the literature since 2010 found 42 articles regarding PGT in clinical nursing settings on PubMed and ProQuest. RESULTS: Despite continuing rises in health care costs, new biotechnology has led to a decrease in the cost of genetic sequencing and application of PGT to practice. CONCLUSION: As PGT becomes increasingly prevalent, nurses should be knowledgeable of its purpose, possibilities, and potential limitations to provide accurate and up-to-date patient information.

Keywords

evidence-based practice psychopharmacology general quality improvement

Get full access to this article

View all access options for this article.

References

Abul-Husn

N. S.

Owusu Obeng

Sanderson

S. C.

Gottesman

Scott

S. A.

(2014). Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine, 7, 227-240. doi:10.2147/PGPM.S48887

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.

Amstutz

Carleton

B. C.

(2011). Pharmacogenetic testing: Time for clinical practice guidelines. Clinical Pharmacology & Therapeutics, 89, 924-927. doi:10.1038/clpt.2011.18

Andrisin

T. E.

Humma

L. M.

Johnson

J. A.

(2002). Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy, 22, 954-960. doi:10.1592/phco.22.12.954.33598

Battelle Technology Partnership Practice. (2012). The economic and functional impacts of genetic and genomic clinical laboratory testing in the United States. Retrieved from http://www.labresultsforlife.org/news/Battelle_Impact_Report.pdf

Belle

D. J.

Singh

(2008). Genetic factors in drug metabolism. American Family Physician, 77, 1553-1560. Retrieved from http://europepmc.org/abstract/med/18581835

Brooks

(2014). Top 100 most prescribed, top-selling drugs. Retrieved from http://www.medscape.com/viewarticle/829246

Carvalho

Zhu

(2014). The Human Genome Project (1990-2003). In The embryo project encyclopedia. Tempe: Arizona State University. Retrieved from http://embryo.asu.edu/pages/human-genome-project-1990-2003

Cascorbi

Tyndale

(2014). Progress in pharmacogenomics: Bridging the gap from research to practice. Clinical Pharmacology & Therapeutics, 95, 231-235. doi:10.1038/clpt.2013.235

10.

Centers for Disease Control and Prevention. (2011). Mental illness surveillance among adults in the United States. Atlanta, GA: Author. Retrieved from http://www.cdc.gov/mmwr/pdf/other/su6003.pdf

11.

Chadwell

(2013). Clinical practice on the horizon: Personalized medicine. Clinical Nurse Specialist, 27, 36-43. doi:10.1097/NUR.0b013e318277703c

12.

Chung

W. K.

(2007). Implementation of genetics to personalize medicine. Gender Medicine, 4, 248-265. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18022591

13.

Crettol

de Leon

Hiemke

Eap

C. B.

(2014). Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine. Clinical Pharmacology & Therapeutics, 95, 254-257. doi:10.1038/clpt.2013.221

14.

Crick

(1970). Central dogma of molecular biology. Nature, 227, 561-563. doi:10.1038/227561a0

15.

DiMatteo

M. R.

Lepper

H. S.

Croghan

T. W.

(2000). Depression is a risk factor for noncompliance with medical treatment. Archives of Internal Medicine, 160, 2101-2107. doi:10.1001/archinte.160.14.2101

16.

Dunnenberger

H. M.

Crews

K. R.

Hoffman

J. M.

Caudle

K. E.

Broeckel

Howard

S. C.

. . . Relling

M. V.

(2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89-106. doi:10.1146/annurev-pharmtox-010814-124835

17.

Fackler

J. L.

McGuire

A. L.

(2009). Paving the way to personalized genomic medicine: Steps to successful implementation. Current Pharmacogenomics and Personalized Medicine, 7, 125. doi:10.2174/187569209788653998

18.

Fagerness

Fonseca

(2014). Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. American Journal of Managed Care, 20(5), e146-e156.

19.

Garfield

L. D.

Dixon

Nowotny

Lotrich

F. E.

Pollock

B. G.

Kristjansson

S. D.

. . . Lenze

E. J.

(2014). Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: Data from a randomized controlled trial. American Journal of Geriatric Psychiatry, 22, 971-979. doi:10.1016/j.jagp.2013.07.003

20.

Goldspiel

B. R.

Flegel

W. A.

DiPatrizio

Sissung

Adams

S. D.

Penzak

S. R.

. . . McKeeby

J. W.

(2014). Integrating pharmacogenetic information and clinical decision support into the electronic health record. Journal of the American Medical Informatics Association, 21, 522-528. doi:10.1136/amiajnl-2013-001873

21.

GoodRx. (2015). Abilify. Retrieved from http://www.goodrx.com/abilify

22.

Greco

Tinley

Seibert

(2012). Essential genetic and genomic competencies for nurses with graduate degrees. Silver Spring, MD: American Nurses Association and International Society of Nurses in Genetics.

23.

Gressier

Ellul

Dutech

Ait Tayeb

A. E. K.

Monfort

Corruble

. . . Verstuyft

(2014). Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression. American Journal of Psychiatry, 171, 890. doi:10.1176/appi.ajp.2014.13101377

24.

Hall-Flavin

D. K.

Winner

J. G.

Allen

J. D.

Carhart

J. M.

Proctor

Snyder

K. A.

. . . Mrazek

D. A.

(2013). Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics, 23, 535-548. doi:10.1097/FPC.0b013e3283649b9a

25.

Hodgkin

(2014, June). Projected US spending on psychotropic medications, 2013-2020. Paper presented at the 5th Biennial Conference of the American Society of Health Economists, Los Angeles, CA. Retrieved from https://ashecon.confex.com/ashecon/2014/webprogram/Paper2382.html

26.

Hung

S.-I.

Chung

W.-H.

Jee

S.-H.

Chen

W.-C. W.-H.

Chang

Y.-T.

Lee

W.-R.

. . . Chen

Y.-T.

(2006). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics, 16, 297-306. doi:10.1097/01.fpc.0000199500.46842.4a

27.

IBM. (2014, March 19). The New York Genome Center and IBM Watson Group announce collaboration to advance genomic medicine. Retrieved from http://www-03.ibm.com/press/us/en/pressrelease/43444.wss

28.

Insel

(2014). Assessing the economic costs of serious mental illness. American Journal of Psychiatry, 165, 663-665.

29.

Johansen Taber

K. A.

Dickinson

B. D

. (2014). Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmacogenomics and Personalized Medicine, 7, 145-162. doi:10.2147/PGPM.S63715

30.

Johnson

J. A.

(2013). Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics, 14, 835-843. doi:10.2217/pgs.13.52

31.

Knisely

M. R.

Carpenter

J. S.

Von Ah

. (2014). Pharmacogenomics in the nursing literature: An integrative review. Nursing Outlook, 62, 285-296. doi:10.1016/j.outlook.2014.03.004

32.

Koola

M. M.

Tsapakis

E. M.

Wright

Smith

Kerwin Rip

R. W.

Nugent

K. L.

Aitchison

K. J.

(2014). Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites? Journal of Psychopharmacology, 28, 665-670. doi:10.1177/0269881114523861

33.

Laje

(2013). Pharmacogenetics of mood disorders: What clinicians need to know. CNS Spectrums, 18, 272-284. doi:10.1017/S1092852913000278

34.

Lam

Y. W. F.

(2013). Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacology, 2013, 1-17. doi:10.1155/2013/641089

35.

Langman

L. J.

Dasgupta

(Eds.). (2012). Pharmacogenomics in clinical therapeutics. Chichester, England: John Wiley. doi:10.1002/9781119959601

36.

Levit

Kassed

Coffey

Mark

McKusick

King

. . . Stranges

(2008). Projections of national expenditures for mental health services and substance abuse treatment, 2004-2014. Rockville, MD: SAMHSA. Retrieved from http://store.samhsa.gov/product/Projections-of-National-Expenditures-for-Mental-Health-Services-and-Substance-Abuse-Treatment-2004-2014/SMA08-4326

37.

Lynch

Price

(2007). The effect of cytochrome p450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76, 391-396.

38.

Malhotra

A. K.

Zhang

J.-P.

Lencz

(2012). Pharmacogenetics in psychiatry: Translating research into clinical practice. Molecular Psychiatry, 17, 760-769. doi:10.1038/mp.2011.146

39.

Man

C. B. L.

Kwan

Baum

Lau

K. M.

Cheng

A. S. H.

M. H. L.

(2007). Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 48, 1015-1018. doi:10.1111/j.1528-1167.2007.01022.x

40.

Mas

Llerena

Saíz

Bernardo

Lafuente

(2012). Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: The potential value of the PEPs study. Pharmacogenomics, 13, 1773-1782. doi:10.2217/pgs.12.159

41.

McMichael

G. L.

Gibson

C. S.

O’Callaghan

M. E.

Goldwater

P. N.

Dekker

G. A.

Haan

E. A.

MacLennan

A. H.

(2009). DNA from buccal swabs suitable for high-throughput SNP multiplex analysis. Journal of Biomolecular Techniques, 20, 232-235.

42.

Millennium Health. (2014). Annual physician notice. Retrieved from http://www.millenniumhealth.com/wp-content/uploads/2015/04/Annual_Physician_Notice_2014_F.pdf

43.

Mulsant

B. H.

(2014). Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014? Canadian Journal of Psychiatry, 59, 59-61.

44.

National Alliance on Mental Illness. (2015). Facts about stigma and mental illness in diverse communities. Retrieved from http://www2.nami.org/ContentManagement/ContentDisplay.cfm?ContentFileID=5148

45.

National Human Genome Research Institute. (2007). A guide to your genome. Retrieved from http://www.genome.gov/Pages/Education/AllAbouttheHumanGenomeProject/GuidetoYourGenome07_vs2.pdf

46.

National Human Genome Research Institute. (2015). DNA sequencing costs. Retrieved from http://www.genome.gov/sequencingcosts/

47.

Needham

(2011). CYP2D6 and CYP2C19 genetic testing for psychiatric drug response. Retrieved from http://www.premierdna.com/wp-content/uploads/2015/07/Psych-El-Camino-Hospital-CYP2D6-and-CYP2C19-Genetic-Testing-for-Psychiatric-Drug-Response.pdf

48.

Pasic

M. D.

Samaan

Yousef

G. M.

(2013). Genomic medicine: New frontiers and new challenges. Clinical Chemistry, 59, 158-167. doi:10.1373/clinchem.2012.184622

49.

PharmGKB. (2015). CPIC: Clinical Pharmacogenetics Implementation Consortium. Retrieved from http://www.pharmgkb.org/page/cpic

50.

Pratt

Brody

(2014). Depression in the U.S. household population, 2009-2012 (NCHS data brief, Vol. 172). Hyattsville, MD: National Center for Health Statistics. Retrieved from http://www.cdc.gov/nchs/data/databriefs/db172.htm

51.

Rejon-Parrilla

J. C.

Nuijten

Redekop

W. K.

Gaultney

J. G.

(2014). Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. Health Policy and Technology, 3, 314-324. doi:10.1016/j.hlpt.2014.08.004

52.

Relling

M. V.

Klein

T. E.

(2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network. Clinical Pharmacology & Therapeutics, 89, 464-467. doi:10.1038/clpt.2010.279

53.

Roche Molecular Diagnostics. (2014). AmpliChip CYP450 test. Retrieved from http://molecular.roche.com/assays/Pages/AmpliChipCYP450Test.aspx

54.

Ross

Anand

S. S.

Joseph

Paré

(2012). Promises and challenges of pharmacogenetics: An overview of study design, methodological and statistical issues. JRSM Cardiovascular Disease, 1(12), 1-13. doi:10.1258/cvd.2012.012001

55.

Rouse

(2015). What is clinical decision support system (CDSS)? (Definition from WhatIs.com). Retrieved from http://searchhealthit.techtarget.com/definition/clinical-decision-support-system-CDSS

56.

Salloum

N. C.

McCarthy

M. J.

Leckband

S. G.

Kelsoe

J. R.

(2014). Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Medicine, 12(90). doi:10.1186/1741-7015-12-90

57.

Shams

T. A.

Müller

D. J.

(2014). Antipsychotic induced weight gain: Genetics, epigenetics, and biomarkers reviewed. Current Psychiatry Reports, 16, 473. doi:10.1007/s11920-014-0473-9

58.

Shuldiner

A. R.

Relling

M. V.

Peterson

J. F.

Hicks

J. K.

Freimuth

R. R.

Sadee

. . . Chute

C. G.

(2013). The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming challenges of real-world implementation. Clinical Pharmacology & Therapeutics, 94, 207-210. doi:10.1038/clpt.2013.59

59.

Smith

D. J.

Evans

Craddock

(2010). Predicting response to lithium in bipolar disorder: A critical review of pharmacogenetic studies. Journal of Mental Health, 19, 142-156. doi:10.3109/09638230903469103

60.

Squassina

Manchia

Manolopoulos

V. G.

Artac

Lappa-Manakou

Karkabouna

. . .Patrinos

G. P.

(2010). Realities and expectations of pharmacogenomics and personalized medicine: Impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 11, 1149-1167. doi:10.2217/pgs.10.97

61.

Stuart

B. C.

Doshi

J. A.

Terza

J. V.

(2009). Assessing the impact of drug use on hospital costs. Health Services Research, 44, 128-144. doi:10.1111/j.1475-6773.2008.00897.x

62.

Substance Abuse and Mental Health Services Administration. (2014). The NSDUH report: State estimates of adult mental illness from the 2011 and 2012 national surveys on drug use and health. Rockville, MD: Author. Retrieved from http://www.samhsa.gov/data/

63.

Swen

J. J.

Huizinga

T. W.

Gelderblom

de Vries

E. G. E.

Assendelft

W. J. J.

Kirchheiner

Guchelaar

H.-J.

(2007). Translating pharmacogenomics: Challenges on the road to the clinic. PLoS Medicine, 4(8), e209. doi:10.1371/journal.pmed.0040209

64.

U.S. Burden of Disease Collaborators. (2013). The state of US health, 1990-2010: Burden of diseases, injuries, and risk factors. Journal of the American Medical Association, 310, 591-608. doi:10.1001/jama.2013.13805

65.

Valenstein

Copeland

L. A.

Blow

F. C.

McCarthy

J. F.

Zeber

J. E.

Gillon

. . . Stavenger

(2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care, 40, 630-639. doi:10.1097/01.MLR.0000021003.43524.64

66.

van’t Veer

L. J.

Dai

van de Vijver

M. J.

Y. D.

Hart

A. A. M.

Mao

. . . Friend

S. H

. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536. doi:10.1038/415530a

67.

The White House. (2015). President Obama’s precision medicine initiative. Retrieved from http://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative

68.

Winner

J. G.

Carhart

J. M.

Altar

Allen

J. D.

Dechairo

B. M.

(2013). A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discovery Medicine, 16, 219-227.

69.

A. C.

Fuhlbrigge

A. L.

(2008). Economic evaluation of pharmacogenetic tests. Clinical Pharmacology & Therapeutics, 84, 272-274. doi:10.1038/clpt.2008.127

70.

Zackrisson

A. L.

Lindblom

Ahlner

(2010). High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clinical Pharmacology & Therapeutics, 88, 354-359. doi:10.1038/clpt.2009.216